{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"47"}]}],"title":"Fatigue had less impact on life, Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"26"}]}],"title":"Fatigue had less impact on life, No"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}]}],"title":"Fatigue had less impact on life, not applicable (N"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"30"}]}],"title":"Soreness in hands/feet had less impact, Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"22"}]}],"title":"Soreness in hands/feet had less impact, No"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"28"}]}],"title":"Soreness in hands/feet had less impact, NA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"32"}]}],"title":"Soreness in mouth/throat had less impact, Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"25"}]}],"title":"Soreness in mouth/throat had less impact, No"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"23"}]}],"title":"Soreness in mouth/throat had less impact, NA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"28"}]}],"title":"Loss of appetite had less impact, Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"28"}]}],"title":"Loss of appetite had less impact, No"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"22"}]}],"title":"Loss of appetite had less impact, NA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"9"}]}],"title":"Change in hair color had less impact, Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"51"}]}],"title":"Change in hair color had less impact, No"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"20"}]}],"title":"Change in hair color had less impact, NA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"32"}]}],"title":"Nausea/vomiting had less impact, Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"30"}]}],"title":"Nausea/vomiting had less impact, No"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"17"}]}],"title":"Nausea/vomiting had less impact, NA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"21"}]}],"title":"Diarrhea had less impact, Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"44"}]}],"title":"Diarrhea had less impact, No"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"15"}]}],"title":"Diarrhea had less impact, NA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"23"}]}],"title":"Pain in stomach area had less impact, Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"30"}]}],"title":"Pain in stomach area had less impact, No"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"27"}]}],"title":"Pain in stomach area had less impact, NA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"44"}]}],"title":"Changes in food tastes had less impact, Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"23"}]}],"title":"Changes in food tastes had less impact, No"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"12"}]}],"title":"Changes in food tastes had less impact, NA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"65"}]}],"title":"Quality of life better, Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"12"}]}],"title":"Quality of life better, No"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}],"title":"Quality of life better, NA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"14"}]}],"title":"Other, Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Other, No"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"66"}]}],"title":"Other, NA"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"description":"The PPQ is used to measure participants' preference for pazopanib or sunitinib for renal cell carcinoma management and is used to determine a participant's preference for 1 of the 2 drugs given in the 2 double-blind treatment periods. Participants were asked to select 1 of the following: 1. prefer the drug taken as the first treatment; 2. prefer the drug taken as the second treatment; or 3, no preference. Those participants who indicated a preference were asked to select the factors that had an influence on their treatment preference, as well as the most important reason for their preference.","groups":[{"description":"Participants received 4 overencapsulated capsules of sunitinib (either in Period 1 or Period 2), each containing 12.5 mg of sunitinib, OD orally for 4 weeks, followed by 2 weeks off treatment (matching placebo capsules to maintain blind), followed by 50 mg (4 x 12.5 mg) OD orally for 4 weeks. Study drug was taken orally OD without food at least one hour before or two hours after a meal. The capsules were swallowed whole and not crushed or broken. The time of day the study drug was taken remained relatively constant.","id":"OG000","title":"Sunitinib"},{"description":"Participants received 4 overencapsulated tablets of pazopanib (either in Period 1 or Period 2), each containing 200 mg of pazopanib, OD orally for 10 weeks. Study drug was taken orally OD without food at least one hour before or two hours after a meal. The capsules were swallowed whole and not crushed or broken. The time of day the study drug was taken remained relatively constant.","id":"OG001","title":"Pazopanib"}],"paramType":"NUMBER","populationDescription":"mITT Population. Responses to some categories of the PPQ may be missing for some participants.","reportingStatus":"POSTED","timeFrame":"End of treatment of both study drugs (maximum of 22 weeks)","title":"Number of Participants Answering \"Yes,\" \"no,\" or Not Applicable (N/A) to the Question of Whether the Indicated Factors Influenced Their Preference for Sunitinib or Pazopanib Treatment as Assessed by the Patient Preference Questionnaire","type":"PRIMARY","unitOfMeasure":"participants"}